Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors

Launched by SUN YAT-SEN UNIVERSITY · Aug 24, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain markers in blood and tissue, as well as imaging features, can help predict the behavior and future risks of pituitary neuroendocrine tumors, specifically pituitary adenomas. These tumors can sometimes be difficult to treat, and this research aims to find early signs that indicate whether these tumors are likely to grow or come back after treatment. By observing changes in these markers and features over time, the study hopes to improve how doctors assess and manage these tumors.

To participate in the trial, individuals must have been diagnosed with a pituitary neuroendocrine tumor, confirmed through imaging studies and hormone tests. However, those with specific conditions, such as certain types of cancer or severe health issues, would not be eligible. Participants can expect to undergo tests that track these markers and imaging features throughout their treatment journey. This study is important because it seeks to provide better tools for doctors to predict outcomes for patients with these complex tumors, ultimately aiming for improved treatment strategies and patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with pituitary neuroendocrine tumors: pituitary adenoma was diagnosed by clinical imaging, with or without pituitary hormone secretion function was confirmed by pituitary hormone detection.
• Exclusion Criteria:
• • 1. Previous pathological specimen suggested pituitary carcinoma.
• • 2. always have received radiation and chemotherapy or immune and targeted therapy of the patients.
• • 3. with known genetic syndrome can cause excessive secretion of hormones (such as Carney syndrome, McCune - Albright syndrome, multiple endocrine neoplasia type 1, acute interstitial pneumonia) patients.
• • 4. there are ectopic neuroendocrine tumor patients.
• • 5. within one month before the screening for major surgery, or within 3 months before screening for patients with sphenoid pituitary surgery.
• • 6. crisis of gland function (the pituitary gland, thyroid crisis, adrenal crisis).
• • 7. peripheral glands or other solid tumors in patients with severe disease or blood system.
• • 8. serious organ damage such as heart, kidney, liver, etc.
• • 9. with severe mental or nervous system disease.
• • 10. serious high blood glucose or poorly controlled hypertension or emergency patients.